Glucagon-like peptide-1 (GLP 1) is a naturally occurring hormone produced by intestinal L-cells after eating. Researchers have shown that GLP-1 plays a central role in regulating appetite and glucose metabolism: it signals the brain to reduce hunger, slows gastric emptying so you feel full longer, and enhances insulin secretion in response to meals, all actions that support sustained weight loss and better metabolic health.
Appetite suppression: GLP-1 activates receptors in the brain’s appetite centers to decrease food intake and cravings, helping people eat less without constant hunger.
Slowed gastric emptying: By delaying how quickly the stomach empties, GLP-1 prolongs satiety after meals and reduces snacking between meals.
Metabolic effects: GLP-1 increases glucose-dependent insulin release and suppresses inappropriate glucagon secretion, improving post-meal blood sugar control and reducing type 2 diabetes risk factors.
How GLP 1 Injections Work in the Body
GLP-1 injections use receptor agonists-medications designed to mimic the naturally occurring hormone glucagon-like peptide-1-to reduce hunger and improve metabolic control.
Enhanced insulin secretion: GLP‑1 receptor activation stimulates glucose-dependent insulin release from the pancreas, improving post-meal glucose and reducing blood sugar spikes
Glucagon suppression: These agents lower inappropriate glucagon release, helping reduce hepatic glucose production and improve overall glucose control.
Slowed gastric emptying: By delaying gastric emptying, GLP‑1 injections prolong fullness after meals, which reduces caloric intake and helps control appetite.
Appetite regulation: GLP‑1 receptor signaling in the brain’s appetite centers decreases hunger and food-seeking behavior, so people typically eat less without increased fatigue or severe cravings.
Combined metabolic outcomes
Together, these peripheral and central effects lower blood sugar, improve insulin dynamics, and reduce calorie intake – a combination that supports weight loss and better type 2 diabetes management.
Who is a Good Candidate for GLP-1 Treatment?
People with:
Obesity – Patients with a BMI meeting local prescribing guidelines (commonly BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities) are typical candidates for GLP-1 therapy. GLP‑1 medications are often considered when lifestyle measures alone have not achieved sufficient weight reduction.
Stubborn fat – People who have persistent central or visceral adiposity despite dieting and exercise may benefit from the body-composition effects of GLP 1 treatment, which preferentially reduce fat mass and waist circumference in many patients.
Difficulty controlling appetite – Individuals who struggle with strong hunger, frequent snacking, or cravings that undermine weight-loss efforts are often good candidates because GLP 1 drugs reduce appetite and help sustain caloric restriction.
If you are in Quezon City and seeking evidence-based weight loss options, GLP-1 receptor agonist treatment is available here at Reshape. Our licensed medical providers perform individual assessments for every patient to ensure a safe and effective plan.
These prescription treatments (for example, semaglutide) can help people reduce body weight, improve blood sugar control, and lower certain cardiometabolic risks when used under appropriate medical supervision.